A microscale HPLC‐UV method for the determination of latamoxef in plasma: An adapted method for therapeutic drug monitoring in neonates. (17th April 2018)

• Record Type: Journal Article
• Authors: Dong, Qian; Shi, Hai‐Yan; Kou, Chen; Huang, Xin; Shen, A‐Dong; Zhao, Wei
• Is Part Of: Biomedical chromatography. Volume 32:Number 8(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-04-17
• Subjects: HPLC -- latamoxef -- neonates -- TDM; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.4243
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: Latamoxef, a broad‐spectrum anti‐bacterial agent of the β ‐lactam antibiotics, is used off‐label in treatment of neonatal sepsis. Large inter‐individual variability and uncertainty of treatment make therapeutic drug monitoring (TDM) useful to optimize antimicrobial therapy. The objective of this study was to develop and validate a simple, selective and reliable HPLC method for the determination of latamoxef in small volumes of plasma, which could be used in neonatal TDM. After a simple protein precipitation, analytes were separated with liquid chromatography and quantified by UV detection, with tinidazole as the internal standard. The calibration range was linear from 3.0 to 60.0 μg/mL. Intra‐ and inter‐day precisions were < 7.2%. The acceptance criteria of accuracy (between 85 and 115%, 120% for lower limit of quantification) were met in all cases. A plasma volume of 50 μL was required to achieve the limit of quantification of 3.0 μg/mL. The TDM results showed a large variability in trough concentrations. A large number of patients were underdosed, highlighting the unmet need for TDM to optimize latamoxef therapy in neonates.